Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner xarelto joint pain (rivaroxaban) and suffered significant bleeding events. Pharmaceutical organizations, which includes the makers of Xarelto, possess a duty to ensure that their drugs are reasonably safe for use – and failure to accomplish so may be grounds for compensation. Our lawyers are operating tough to have those hurt by the drug the compensation they may be entitled to.
Even though bleeding is a typical complication associated with anticoagulants, it has been alleged that Xarelto is more hazardous than standard blood thinners since no antidote exists to reverse its blood-thinning effects. This indicates that, inside the occasion of an emergency, sufferers could be at risk for irreversible bleeding difficulties, including life-threatening internal and gastrointestinal hemorrhaging.
In the event you or possibly a loved one suffered a critical bleeding event right after taking Xarelto, you may have legal recourse. For much more information, contact us nowadays to have your case reviewed, free of charge of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for previous and future healthcare bills, lost wages, discomfort and suffering and, in instances of death, funeral expenses. In addition, they are searching for punitive damages, that are normally awarded to punish the defendant and deter other organizations from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike classic anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Simply because of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding inside the occasion of an emergency. Plaintiffs in the lawsuits allege serious and fatal injuries, which includes cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user within the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to critical bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing unsafe clotting.
Visit this page for more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.